The length of the product is 135mm, Ø 53mm.
The volume of the Alteco LPS Adsorber is 100ml.
The housing and end-caps are made of an acrylic-based polymer compound. The porous discs are made of polyethylene (HDPE resin).
No, this was studied in detail in the product development process and there are no toxic materials or substances in the Alteco LPS Adsorber.
The Alteco LPS Adsorber uses a surface area of >3m2. When blood comes into contact with large artificial surfaces, it induces a systemic response. 1 The smaller the surface area, the less complement activation in the immune system – hence, an optimized surface area is beneficial.
The shelf life of the Alteco LPS Adsorber is 3 years.
The Alteco LPS Adsorber is intended for use with standard, commercially available bloodlines compatible with the acute blood purification system used.
Start treatment with the Alteco LPS Adsorber when the following clinical parameters are met:
• Urine production is decreasing (acute kidney failure approaching)
• Mean arterial pressure (MAP) ~ 65 mmHg
• >2 hours of vasopressor support and patient still unstable
A double lumen dialysis catheter of size 12-14F is required to obtain sufficient blood flow rate of 150 ± 50 ml/min. A femoral Seldinger catheter can also be used.
The Alteco LPS Adsorber can be primed manually, or automatically when connected to the tubing in the blood pump machine circuit. If automatic priming is used, follow the machine’s instruction for use (IFU). Manual priming takes approximately 5 minutes.
Rinsing of the Alteco LPS Adsorber is important to wash out the glycerin used as a stabilizer in the adsorber.
The recommended treatment time with Alteco LPS Adsorber is two hours in hemoperfusion. However, the product can be used for up to 6 hours and treatment can be repeated if needed.
Due to the importance of early treatment, the recommended treatment mode is hemoperfusion mode (stand-alone).
The recommended flow when using the Alteco LPS Adsorber is 150 ± 50ml/min (minimum 100ml/min and maximum 200ml/min).
Usually, one treatment is sufficient, but treatment can be repeated if needed. One treatment equals one device.
Yes. The scope of use for the product is extracorporeal treatments. The recommended treatment mode is hemoperfusion, but it can be used in CRRT as well. We are very interested in getting case reports! If placed in series with a dialysis membrane, the Alteco LPS Adsorber shall be placed before the dialysis membrane and blood flow must not exceed 150 ±50 ml/min during the treatment.
The Alteco LPS Adsorber may be used on COVID-19 patients suspected to have gram-negative bacterial infection and/or signs of inflammatory response/sepsis. Seasonal flu and viral infections, including COVID-19, can also cause sepsis. 2 The Alteco LPS Adsorber is used as an add-on treatment in sepsis and does not treat COVID-19.
90% of patients with severe pulmonary forms of COVID-19 have increased endotoxin levels and the level of endotoxin is directly related to the severity of COVID-19. Studies have shown that endotoxin adsorption results in clinical improvement in severe COVID-19 patients with elevated endotoxin levels. 3
No, the Alteco LPS Adsorber is meant for single use only and cannot be resterilized.
Take endotoxin out of the picture
View our product animation to learn more about endotoxin removal and the Alteco LPS Adsorber.
Applications
Manage sepsis in the ICU
Learn more about Alteco LPS Adsorber for treating sepsis and septic shock.
Preventive endotoxin removal in cardiac surgery
Endotoxin from gram-negative bacteria is a potent trigger of the inflammatory response, and endotoxemia is known to occur in cardiac surgery using extracorporeal circulation.
Sepsis in COVID-19 ICU patients
Learn more about Alteco LPS Adsorber for treating sepsis and septic shock in COVID-19 ICU patients, and the rationale for removing endotoxin.
1 Sepsis After Cardiac Surgery: From Pathophysiology to Management
2 WHO calls for global action on sepsis – cause of 1 in 5 deaths worldwide
3 Peerapornratana, S., Sirivongrangson, P., Tungsanga, S., Tiankanon, K., Kulvichit, W., Putcharoen, O., Kellum, J. A., & Srisawat, N. (2022). Endotoxin Adsorbent Therapy in Severe COVID-19 Pneumonia. Blood purification, 51(1), 47–54.
